Mga Batayang Estadistika
| LEI | 5493007G7UTDFV38SP78 |
| CIK | 1302573 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OptMed Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| May 3, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. 15-12B FORM 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35993 OncoMed Pharmaceuticals, Inc. (Exact name of registrant as specif |
|
| April 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68234X102 (CUSIP Number) JAMES KRATKY BVF |
|
| April 24, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on April 24, 2019 Registration Statement No. |
|
| April 24, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on April 24, 2019 Registration Statement No. |
|
| April 24, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on April 24, 2019 Registration Statement No. |
|
| April 24, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on April 24, 2019 Registration Statement No. |
|
| April 24, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on April 24, 2019 Registration Statement No. |
|
| April 24, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on April 24, 2019 Registration Statement No. |
|
| April 23, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2019 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporatio |
|
| April 23, 2019 |
Amended and Restated Bylaws of OncoMed Pharmaceuticals, Inc. EX-3.2 3 d735482dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ONCOMED PHARMACEUTICALS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the |
|
| April 23, 2019 |
Amended and Restated Certificate of Incorporation of OncoMed Pharmaceuticals, Inc. EX-3.1 2 d735482dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ONCOMED PHARMACEUTICALS, INC. FIRST: The name of the corporation is OncoMed Pharmaceuticals, Inc. (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of its registered a |
|
| April 17, 2019 |
Other Events, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2019 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (C |
|
| April 17, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. 8-K (Merger Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2019 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (C |
|
| March 20, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. DEFM14A DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2019 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. |
|
| March 15, 2019 |
Form of Stockholder Support Agreement EX-10.2 Exhibit 10.2 STOCKHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of March , 2019 (the “Effective Date”), is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and [insert name of stockholder] (“Stockholder”). WHEREAS, in connection with that certain Agreement and Plan of Merger and Reorganization, dated as of December 5, |
|
| March 15, 2019 |
EX-10.1 2 d709280dex101.htm EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN ONCOMED PHARMACEUTICALS, INC. and COMPUTERSHARE INC. Dated as of March 14, 2019 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions 1 ARTICLE 2 CONTINGENT VALUE RIGHTS 4 Section 2.1 Holders of CVRs; Appointment of Rights Agent; Assignment of Rights 4 Section 2.2 Non-transferable 5 Section |
|
| March 15, 2019 |
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights EX-99.1 4 d709280dex991.htm EX-99.1 Exhibit 99.1 OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors decl |
|
| March 15, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2019 (March 14, 2019) ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdictio |
|
| March 15, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2019 (March 14, 2019) ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdictio |
|
| March 15, 2019 |
EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN ONCOMED PHARMACEUTICALS, INC. and COMPUTERSHARE INC. Dated as of March 14, 2019 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions 1 ARTICLE 2 CONTINGENT VALUE RIGHTS 4 Section 2.1 Holders of CVRs; Appointment of Rights Agent; Assignment of Rights 4 Section 2.2 Non-transferable 5 Section 2.3 No Certificate; Registra |
|
| March 15, 2019 |
Form of Stockholder Support Agreement EX-10.2 Exhibit 10.2 STOCKHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of March , 2019 (the “Effective Date”), is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and [insert name of stockholder] (“Stockholder”). WHEREAS, in connection with that certain Agreement and Plan of Merger and Reorganization, dated as of December 5, |
|
| March 15, 2019 |
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights EX-99.1 Exhibit 99.1 OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special divi |
|
| March 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68234X102 (CUSIP Number) JAMES KRATKY BVF P |
|
| March 15, 2019 |
JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated March 15, 2019 (including amendments thereto) with respect to the shares of Common Stock $0. |
|
| March 12, 2019 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. |
|
| March 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commis |
|
| March 7, 2019 |
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results EX-99.1 2 omed-ex9916.htm EX-99.1 Exhibit 99.1 OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results REDWOOD CITY, Calif., March 7, 2019 (GLOBE NEWSWIRE) - OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced fourth quarter and full year 2018 financial results. R |
|
| March 7, 2019 |
Exhibit 10.17 ONCOMED LETTERHEAD October 17, 2018 John Lewicki ### ####### ### ### #####, ## ##### Re:Amended and Restated Change in Control and Severance Agreement Dear John: You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to an Amended and Restated Change in Control and Severance Agreement dated October 14, 2015 (the “Change in Control Agreement”), which sets forth, among other |
|
| March 7, 2019 |
Sublease, dated October 26, 2018, by and between the registrant and Venn Biosciences Corporation Exhibit 10.4 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of October 26, 2018, and is made by and between ONCOMED PHARMACEUTICALS, INC., a Delaware corporation (“Sublandlord”), and VENN BIOSCIENCES CORPORATION, a Delaware corporation (“Subtenant”). Sublandlord and Subtenant hereby agree as follows: 1.Recitals: This Sublease is made with reference to the fact that HCP |
|
| March 7, 2019 |
Sublease, dated January 16, 2019, by and between the registrant and Revolution Medicines, Inc. Exhibit 10.5 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of January 16, 2019, and is made by and between ONCOMED PHARMACEUTICALS, INC., a Delaware corporation (“Sublandlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Subtenant”). Sublandlord and Subtenant hereby agree as follows: 1. Recitals: This Sublease is made with reference to the fact that HCP |
|
| March 7, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35993 OncoMed Pharma |
|
| March 7, 2019 |
Separation Agreement, dated December 5, 2018, by and between the registrant and Austin Gurney EX-10.9(E) 4 omed-ex109e116.htm EX-10.9(E) Exhibit 10.9(E) ONCOMED LETTERHEAD December 5, 2018 Austin Gurney, Ph.D. ### ###### ## ### #########, ## ##### Dear Austin: This letter confirms the offer made to you by OncoMed Pharmaceuticals, Inc. (the “Company”) in conjunction with your continued employment and separation from the Company as of December 21, 2018, or such earlier date as either you or |
|
| February 22, 2019 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. |
|
| February 15, 2019 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) 425 1 dp102364425.htm FORM 425 Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. Date: February 15, 2019. (Subject Company Commission File No.: 001-35993) February 2019 COMBINATION OF MEREO AND ONCOMED DISCLAIMER 1 Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended t |
|
| February 14, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) common stock, par value $0.001 per share (Title of Class of Securities) 68234X 10 2 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. / HARBOURVEST PARTNERS LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oncomed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68234X102 (CUSIP Number) Dece |
|
| February 13, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. / Phase4 Partners Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No: 2)* Under the Securities Exchange Act of 1934 (Amendment No. ) OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68234X102 (CUSIP Number) December 17, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 12, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. / DELPHI VENTURES VIII LP - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing |
|
| February 11, 2019 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. |
|
| February 11, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. 425 (Prospectus) 425 Filed by OncoMed Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: OncoMed Pharmaceuticals, Inc. (Commission File No.: 001-35993) February 2019 Combination of Mereo AND ONCOMED Disclaimer Mereo BioPharma Group plc No Offer or Solicitation This communication is not inten |
|
| February 8, 2019 |
OMED / OncoMed Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| January 28, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2019 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporat |
|
| January 7, 2019 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. |
|
| December 21, 2018 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.1 2 d677524dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this |
|
| December 21, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. / HARBOURVEST PARTNERS LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oncomed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68234X102 (CUSIP Number) December 17, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| December 17, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. / Mereo Biopharma Group Plc - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 68234X102 (CUSIP Number) Charles Sermon General Counsel Mereo BioPharma Group plc 4th Floor, 1 Cavendish Place London WIG 0QF United Kingdom Tel. No.: +44 |
|
| December 17, 2018 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.001 par value per share, of OncoMed Pharmaceuticals, Inc. and (ii) that this |
|
| December 11, 2018 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed Pharmaceuticals, Inc. |
|
| December 6, 2018 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) EX-99.3 Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. Date: December 6, 2018. This filing relates to a proposed merger of Mereo BioPharma Group plc with OncoMed Pharmaceuticals, Inc. (Subject Company Commission File No.: 001-35993) Exhibit 99.3 Mereo BioPharma Group |
|
| December 6, 2018 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. |
|
| December 6, 2018 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. |
|
| December 6, 2018 |
MREO / Mereo BioPharma Group plc FORM 425 (Prospectus) Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. |
|
| December 6, 2018 |
EX-10.1 Exhibit 10.1 FORM OF STOCKHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales (“Milan”), and [insert name of stockholder] (“Stockholder”). WHEREAS, in order to induce Milan and Mereo MergerCo One Inc., a Delaware corporati |
|
| December 6, 2018 |
EX-10.4 Exhibit 10.4 SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company |
|
| December 6, 2018 |
EX-10.2 Exhibit 10.2 FORM OF SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [insert name of shareholder] (“Shareholder”). WHEREAS, in order to induce the Company to enter into an Agreement and Plan of Merger and Reorganization, dated as of the da |
|
| December 6, 2018 |
EX-99.2 5 December 2018 Combination of Mereo BioPharma and OncoMed Pharmaceuticals Exhibit 99.2 Disclaimer Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdi |
|
| December 6, 2018 |
Mereo BioPharma Group PLC (OncoMed) December 5, 2018 EX-99.3 Exhibit 99.3 Mereo BioPharma Group PLC (OncoMed) December 5, 2018 Corporate Speakers: • Denise Scots-Knight; Mereo BioPharma; CEO • Richard Jones; Mereo BioPharma; CFO • John Lewicki; OncoMed Pharmaceuticals, Inc.; President, CEO Participants: • Brian White; Cantor Fitzgerald; Analyst • Lala Gregorek; Trinity Delta; Analyst • Samir Devani; Rx Securities Limited; Analyst PRESENTATION Operat |
|
| December 6, 2018 |
EX-10.7 9 d665634dex107.htm EX-10.7 Exhibit 10.7 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN MEREO BIOPHARMA GROUP PLC and COMPUTERSHARE INC. Dated as of [ ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions 1 ARTICLE 2 CONTINGENT VALUE RIGHTS 7 Section 2.1 Holders of CVRs; Appointment of Rights Agent 7 Section 2.2 Non-transferable 7 Section 2.3 No Certificate; Registrat |
|
| December 6, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2018 (December 5, 2018) ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction |
|
| December 6, 2018 |
EX-99.1 Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals To be effected by an all-stock transaction plus issuance of Contingent Value Rights (“CVRs”); comp |
|
| December 6, 2018 |
Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and Novartis Pharma AG. EX-10.3 Exhibit 10.3 EXECUTION VERSION FORM OF SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a Swiss corporation (“Shareholder”). WHEREAS, in order to induce the Company to enter into an Agreement and Plan of Merger and Reorg |
|
| December 6, 2018 |
EX-10.5 Exhibit 10.5 SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company |
|
| December 6, 2018 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: MEREO BIOPHARMA GROUP PLC, a public limited company incorporated under the laws of England and Wales; MEREO US HOLDINGS INC., a Delaware corporation; MEREO MERGERCO ONE INC., a Delaware corporation; and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation Dated as of December 5, 2018 Table of Contents Page |
|
| December 6, 2018 |
EX-10.6 Exhibit 10.6 SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company |
|
| December 6, 2018 |
EX-10.1 Exhibit 10.1 FORM OF STOCKHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales (“Milan”), and [insert name of stockholder] (“Stockholder”). WHEREAS, in order to induce Milan and Mereo MergerCo One Inc., a Delaware corporati |
|
| December 6, 2018 |
EX-10.5 7 d665634dex105.htm EX-10.5 Exhibit 10.5 SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company li |
|
| December 6, 2018 |
EX-10.4 6 d665634dex104.htm EX-10.4 Exhibit 10.4 SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company li |
|
| December 6, 2018 |
Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and Novartis Pharma AG. EX-10.3 5 d665634dex103.htm EX-10.3 Exhibit 10.3 EXECUTION VERSION FORM OF SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a Swiss corporation (“Shareholder”). WHEREAS, in order to induce the Company to enter into an Agreement |
|
| December 6, 2018 |
EX-10.7 Exhibit 10.7 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN MEREO BIOPHARMA GROUP PLC and COMPUTERSHARE INC. Dated as of [ ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions 1 ARTICLE 2 CONTINGENT VALUE RIGHTS 7 Section 2.1 Holders of CVRs; Appointment of Rights Agent 7 Section 2.2 Non-transferable 7 Section 2.3 No Certificate; Registration; Registration of Transfe |
|
| December 6, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2018 (December 5, 2018) ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction |
|
| December 6, 2018 |
Mereo BioPharma Group PLC (OncoMed) December 5, 2018 EX-99.3 12 d665634dex993.htm EX-99.3 Exhibit 99.3 Mereo BioPharma Group PLC (OncoMed) December 5, 2018 Corporate Speakers: • Denise Scots-Knight; Mereo BioPharma; CEO • Richard Jones; Mereo BioPharma; CFO • John Lewicki; OncoMed Pharmaceuticals, Inc.; President, CEO Participants: • Brian White; Cantor Fitzgerald; Analyst • Lala Gregorek; Trinity Delta; Analyst • Samir Devani; Rx Securities Limited |
|
| December 6, 2018 |
EX-99.1 10 d665634dex991.htm EX-99.1 Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals To be effected by an all-stock transaction plus issuance of Contingen |
|
| December 6, 2018 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: MEREO BIOPHARMA GROUP PLC, a public limited company incorporated under the laws of England and Wales; MEREO US HOLDINGS INC., a Delaware corporation; MEREO MERGERCO ONE INC., a Delaware corporation; and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation Dated as of December 5, 2018 Table of Contents Page |
|
| December 6, 2018 |
EX-10.6 Exhibit 10.6 SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company |
|
| December 6, 2018 |
EX-10.2 Exhibit 10.2 FORM OF SHAREHOLDER SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [insert name of shareholder] (“Shareholder”). WHEREAS, in order to induce the Company to enter into an Agreement and Plan of Merger and Reorganization, dated as of the da |
|
| December 6, 2018 |
EX-99.2 5 December 2018 Combination of Mereo BioPharma and OncoMed Pharmaceuticals Exhibit 99.2 Disclaimer Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdi |
|
| November 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Com |
|
| November 1, 2018 |
Exhibit 99.1 OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights -Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation of etigilimab data at Society for Immunotherapy of Cancer (SITC) Annual Meeting REDWOOD CITY, Calif., November 1, 2018 (GLOBE NEWS |
|
| November 1, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35993 OncoM |
|
| October 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Com |
|
| October 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (C |
|
| September 20, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (C |
|
| September 20, 2018 |
OncoMed Provides Update on Navicixizumab Partnership EX-99.1 2 omed-ex9918.htm EX-99.1 Exhibit 99.1 September 20, 2018 OncoMed Provides Update on Navicixizumab Partnership REDWOOD CITY, CA – September 20, 2018 – OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Celgene has notified OncoMed that due to strategic product por |
|
| August 2, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commi |
|
| August 2, 2018 |
Exhibit 99.1 August 2, 2018 OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights -Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018- -Cash runway extended by an additional quarter to YE 2019- REDWOOD CITY, Calif., August 2, 2018 (GLOBE NEWSWIRE) - OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a cl |
|
| August 2, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 omed-10q20180630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 2, 2018 |
Exhibit 10.1 AMENDMENT 6 TO THE COLLABORATION AND OPTION AGREEMENT This Amendment 6 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on June 13, 2018 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer AG, a Ge |
|
| June 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of i |
|
| June 25, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commis |
|
| June 18, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. CORRESP CORRESP OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, California 94063 June 18, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey Gabor Erin Jaskot Re: OncoMed Pharmaceuticals, Inc. Registration Statement on Form S-3 (Registration No. 333-225225) Ladies and Gentlemen: In accordance with Ru |
|
| May 25, 2018 |
EX-1.2B Exhibit 1.2B Amendment No. 1 to the Controlled Equity OfferingSM Sales Agreement This Amendment No. 1 (this “Amendment”) is effective as of March 22, 2018 (the “Amendment Date”), and modifies the Controlled Equity OfferingSM Sales Agreement, dated June 12, 2015 (the “Sales Agreement”), by and between Cantor Fitzgerald & Co. (“CF&Co”) and OncoMed Pharmaceuticals, Inc. (“OncoMed”). OncoMed a |
|
| May 25, 2018 |
EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIOS The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated (in thousands): Three Months Ended March 31, Year Ended December 31, 2018 2017 2016 2015 2014 2013 EARNINGS: Loss before income taxes $ (5,569 ) $ (40,145 ) $ (103,088 ) $ (85,387 ) $ (50,519 ) $ (24,127 ) Plus fixed charges and |
|
| May 25, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. REGISTRATION STATEMENT ON FORM S-3 Registration Statement on Form S-3 Table of Contents As filed with the Securities and Exchange Commission on May 25, 2018 Registration No. |
|
| May 25, 2018 |
EX-4.4 3 d571136dex44.htm EX-4.4 Exhibit 4.4 OncoMed Pharmaceuticals, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Iss |
|
| May 8, 2018 |
Exhibit 99.1 May 8, 2018 OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights Q1 Cash Balance of $88.4 Million—Cash through Q3 2019 First patient expected to be dosed in Phase 1b portion of anti-TIGIT trial in second quarter of 2018 Navicixizumab data expected in second half of 2018 REDWOOD CITY, Calif. – May 8, 2018 – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a cl |
|
| May 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commissi |
|
| May 8, 2018 |
Exhibit 10.1 ONCOMED PHARMACEUTICALS, INC. Non-Employee DIRECTOR COMPENSATION POLICY Approved by the Board of Directors on August 28, 2013, as amended October 14, 2013, February 28, 2014, June 24, 2015, and March 1, 2018 Non-employee members of the board of directors (the “Board”) of OncoMed Pharmaceuticals, Inc. (the “Company”) who are appointed to the Board following the date upon which the Comp |
|
| May 8, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. OMED-Q1-20180331 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35993 OncoMed P |
|
| April 27, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 27, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commi |
|
| March 9, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35993 OncoMed Pharma |
|
| March 9, 2018 |
Form of Retention Bonus Agreement for officers Exhibit 10.13 January 25, 2018 [Employee name] [Employee address] Dear [Employee]: This letter (the “Retention Bonus Agreement”) provides terms regarding your eligibility for retention bonus compensation from OncoMed Pharmaceuticals, Inc. (“OncoMed”). Retention Bonus Eligibility If you remain actively employed with OncoMed in good standing through December 31, 2018 (the “Retention Period”), you wi |
|
| March 9, 2018 |
Exhibit 10.7(D) ONCOMED LETTERHEAD January 1, 2018 Paul J. Hastings ## ######## ## ### #########, ## ##### Re: Your Resignation of Employment and Board Positions Dear Paul: This letter agreement (this “Agreement”) confirms our recent discussions about your employment as Chairman, President and CEO of OncoMed Pharmaceuticals, Inc. (the “Company”). As you know, you and the Company entered into an of |
|
| March 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commis |
|
| March 8, 2018 |
Exhibit 99.1 March 8, 2018 OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights Navicixizumab and anti-TIGIT data expected in the 2nd Half of 2018 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT REDWOOD CITY, Calif. – March 8, 2018 – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical |
|
| February 27, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment SC 13G/A 1 a18-711336sc13ga.htm SC 13G/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . .10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncomed Pharmaceuticals (Name of Issuer) Common (Title of Class of Securities) 68234X102 |
|
| February 23, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. 8-K/A_5.02_FEB2018 (Current Report) omed-8ka20180223.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or |
|
| February 14, 2018 |
SC 13G/A 1 sc13ga20742202902142018.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0 |
|
| February 14, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. / MORGENTHALER PARTNERS VII LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock ($0.001 par value) (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2017 (Date of Event Whi |
|
| February 14, 2018 |
Amendment No 1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 13, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. / DELPHI VENTURES VIII LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing |
|
| January 31, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. 8-K (Current Report) omed-8k20180126.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of |
|
| January 31, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. / US VENTURE PARTNERS VIII L P - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 4)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing |
|
| January 4, 2018 |
OMED / OncoMed Pharmaceuticals, Inc. FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on January 4, 2018 Registration No. |
|
| January 4, 2018 |
EX-99.1 Exhibit 99.1 January 4, 2018 OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program Year-end 2017 Cash Balance of $103.1 Million Presentation of Clinical Data on Phase 1 programs expected in 2018 REDWOOD CITY, Calif. ? January 4, 2018 ? OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused |
|
| January 4, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2018 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporati |
|
| December 6, 2017 |
OMED / OncoMed Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OncoMed Pharmaceuticals, Inc. (Name of Issuer) common stock, par value $0.001 per share (Title of Class of Securities) 68234X 10 2 (CUSIP Number) November 6, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 2, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20171102.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of |
|
| November 2, 2017 |
omed-ex9918.htm Exhibit 99.1 November 2, 2017 OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT REDWOOD CITY, Calif. – November |
|
| November 2, 2017 |
OMED / OncoMed Pharmaceuticals, Inc. 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35993 OncoM |
|
| November 2, 2017 |
Exhibit 10.1 CONFIDENTIALLONZA AMENDMENT NO.3 to the Multi-Product License Agreement dated 22 August 2012 between LONZA SALES AG and ONCOMED PHARMACEUTICALS, INC CONFIDENTIALLONZA THIS AMENDMENT is made the 26 day of August 2016 BETWEEN LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referre |
|
| September 19, 2017 |
EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence Office of the President Established to Lead Company during Medical Leave REDWOOD CITY, Calif. ? September 19, 2017 ? OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today a |
|
| September 19, 2017 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorpor |
|
| August 2, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition omed-8k20170802.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of i |
|
| August 2, 2017 |
EX-99.1 2 omed-ex9918.htm EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Announces Second Quarter 2017 Financial Results Wholly-owned Immuno-oncology Candidate GITRL-Fc to enter clinic in 2H 2017 Q2 Cash Balance of $129.8M – Cash Through Q3 2019 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT REDWOOD CITY, Calif. – August 2nd, 2017 – OncoMed Pharmaceuti |
|
| August 2, 2017 |
OMED / OncoMed Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35993 OncoMed Ph |
|
| July 10, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20170707.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of inc |
|
| June 6, 2017 |
OMED / OncoMed Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G Passive Investment SC 13G 1 a17-147652sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . . 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oncomed Pharmaceuticals (Name of Issuer) Common (Title of Class of Securities) 68234X102 (CUS |
|
| June 5, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20170601.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of inc |
|
| May 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68234X102 (CUSIP Number) May |
|
| May 8, 2017 |
OncoMed Pharmaceuticals 10-Q (Quarterly Report) omed-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| May 8, 2017 |
omed-ex9918.htm Exhibit 99.1 For Immediate Release OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results Q1 Cash Balance of $156.9M ? Cash Through Q3 2019 Phase 2 Demcizumab DENALI Non-Small Cell Lung Cancer Trial Did Not Meet Endpoints Focused on Immuno-Oncology Pipeline and Celgene Collaboration Programs Management to Host Conference Call/Webcast this Morning at 8: |
|
| May 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events omed-8k20170508.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of inco |
|
| April 28, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20170424.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of i |
|
| April 27, 2017 |
EX-99.1 2 ex991to13g0742202904272017.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated April 27, 2017 with respect to the shares of Common Stock of OncoMed Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuan |
|
| April 27, 2017 |
SC 13G 1 sc13g0742202904272017.htm THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of |
|
| April 17, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20170417.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of i |
|
| April 17, 2017 |
omed-ex9916.htm Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed?s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints Company also Announces Discontinuation of Brontictuzumab Phase 1b Study OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results REDWOOD CITY, Calif., April 17, 2017 ? OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED |
|
| April 13, 2017 |
OncoMed Pharmaceuticals DEFA14A omed-defa14a20160622.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 13, 2017 |
OncoMed Pharmaceuticals DEF 14A omed-def14a20170601.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by R |
|
| April 10, 2017 |
omed-ex9919.htm Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed’s Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results REDWOOD CITY, Calif., April 10, 2017 – OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing |
|
| April 10, 2017 |
omed-ex9928.htm Exhibit 99.2 OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept OncoMed Retains Worldwide Rights to Both Wnt Pathway Programs Redwood City, CA, – April 10, 2017 – OncoMed Pharmaceuticals, Inc. (XNAS: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology |
|
| April 10, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20170410.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of i |
|
| March 9, 2017 |
OncoMed Pharmaceuticals 10K (Annual Report) omed-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| March 9, 2017 |
Exhibit 10.2(F) AMENDMENT 5 TO THE COLLABORATION AND OPTION AGREEMENT This Amendment 5 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into as of December 15, 2016 (the “Amendment Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”) |
|
| March 9, 2017 |
Exhibit 10.5(D) THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this "Third Amendment") is made and entered into as of the 11 day of November, 2016, by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company ("Landlord"), and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A.Landlord (as successor in interest to Slough Redwood City, LL |
|
| March 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition omed-8k20170308.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of in |
|
| March 8, 2017 |
omed-ex99137.htm Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT REDWOOD CITY, Calif., March 8, 2017 – OncoMed |
|
| February 13, 2017 |
OMED / OncoMed Pharmaceuticals, Inc. / US VENTURE PARTNERS VIII L P - SC 13G/A Passive Investment SC 13G/A 1 v458821sc13g-a.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 201 |
|
| February 13, 2017 |
OncoMed Pharmaceuticals AMENDMENT NO. 1 (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 13, 2017 |
OncoMed Pharmaceuticals SC 13G/A (Passive Acquisition of More Than 5% of Shares) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) January 10, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 5, 2017 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20170105.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2017 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of |
|
| January 5, 2017 |
omed-ex99145.htm Exhibit 99.1 For Immediate Release OncoMed Announces Year-End Cash Balance and 2017 Outlook Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif. ? January 5, 2017 ? OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage company focused on discovering and developing novel anti-cancer |
|
| January 4, 2017 |
S-8 As filed with the Securities and Exchange Commission on January 3, 2017 Registration No. |
|
| December 6, 2016 |
OncoMed Pharmaceuticals 8-K - ITEM 5.02 (Current Report/Significant Event) omed-8k20161202.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of |
|
| November 1, 2016 |
OncoMed Pharmaceuticals 10-Q (Quarterly Report) omed-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| November 1, 2016 |
omed-ex99148.htm Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results Ends Quarter with $207 Million Cash Enrollment Complete in Phase 2 Trials for Demcizumab and Tarextumab; On Track for Data in 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT REDWOOD CITY, Calif., November 1, 2016 ? OncoMed P |
|
| November 1, 2016 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) omed-8k20161101.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of |
|
| November 1, 2016 |
Exhibit 10.1 AMENDMENT 4 TO THE COLLABORATION AND OPTION AGREEMENT This Amendment 4 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müller |
|
| August 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68234X102 (CUSIP Num |
|
| August 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68234X102 (CUSIP Num |
|
| August 26, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G dated on the date hereof with respect to the Common Stock, $0.001 par value per share, of OncoMed Pharmaceuticals, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rul |
|
| August 24, 2016 |
OMED / OncoMed Pharmaceuticals, Inc. / CELGENE CORP /DE/ - SCHEDULE 13G Passive Investment SC 13G 1 t1602061sc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) August 23, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| August 24, 2016 |
OMED / OncoMed Pharmaceuticals, Inc. / CELGENE CORP /DE/ - SCHEDULE 13G Passive Investment SC 13G 1 t1602061sc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) August 23, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| August 23, 2016 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporati |
|
| August 23, 2016 |
OncoMed Pharmaceuticals, Inc. 5,500,000 Shares of Common Stock Underwriting Agreement EX-1.1 Exhibit 1.1 EXECUTION VERSION OncoMed Pharmaceuticals, Inc. 5,500,000 Shares of Common Stock Underwriting Agreement August 17, 2016 Leerink Partners LLC As representative of the several Underwriters named in Schedule I hereto (the ?Representative?), c/o Leerink Partners LLC 299 Park Avenue 21st Floor New York, NY 10171 Ladies and Gentlemen: OncoMed Pharmaceuticals, Inc., a Delaware corporat |
|
| August 23, 2016 |
OncoMed Pharmaceuticals, Inc. 5,500,000 Shares of Common Stock Underwriting Agreement EX-1.1 Exhibit 1.1 EXECUTION VERSION OncoMed Pharmaceuticals, Inc. 5,500,000 Shares of Common Stock Underwriting Agreement August 17, 2016 Leerink Partners LLC As representative of the several Underwriters named in Schedule I hereto (the ?Representative?), c/o Leerink Partners LLC 299 Park Avenue 21st Floor New York, NY 10171 Ladies and Gentlemen: OncoMed Pharmaceuticals, Inc., a Delaware corporat |
|
| August 23, 2016 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporati |
|
| August 19, 2016 |
5,500,000 Shares OncoMed Pharmaceuticals, Inc. Common Stock 424B5 1 d229153d424b5.htm FILED PURSUANT TO RULE 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-204914 PROSPECTUS SUPPLEMENT (To Prospectus dated July 22, 2015) 5,500,000 Shares OncoMed Pharmaceuticals, Inc. Common Stock We are offering up to 5,500,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Select Market under the sy |
|
| August 19, 2016 |
5,500,000 Shares OncoMed Pharmaceuticals, Inc. Common Stock 424B5 1 d229153d424b5.htm FILED PURSUANT TO RULE 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-204914 PROSPECTUS SUPPLEMENT (To Prospectus dated July 22, 2015) 5,500,000 Shares OncoMed Pharmaceuticals, Inc. Common Stock We are offering up to 5,500,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Select Market under the sy |
|
| August 17, 2016 |
Subject to completion, dated August 17, 2016. Filed Pursuant to Rule 424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| August 9, 2016 |
OncoMed Pharmaceuticals 10-Q (Quarterly Report) omed-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| August 9, 2016 |
OncoMed Pharmaceuticals 10-Q (Quarterly Report) omed-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| August 9, 2016 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporatio |
|
| August 9, 2016 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporatio |
|
| August 9, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT REDWOOD CITY, Calif., August 9, 2016 ? OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today repo |
|
| August 9, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT REDWOOD CITY, Calif., August 9, 2016 ? OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today repo |
|
| June 24, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commis |
|
| May 5, 2016 |
OncoMed Pharmaceuticals 10-Q (Quarterly Report) omed-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| May 5, 2016 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) |
|
| May 5, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT Highlights AACR Presentations Including Novel GITRL-Fc Candidate Clinical Data on Vantictumab, Ipafricept, Demcizumab and Tarextumab Accepted for Presentation at ASCO REDWOOD CITY, Calif., |
|
| April 29, 2016 |
OncoMed Pharmaceuticals DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2016 |
OncoMed Pharmaceuticals DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2016 |
OMED / OncoMed Pharmaceuticals, Inc. / VERTICAL FUND I LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) March 17, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| March 10, 2016 |
S-8 As filed with the Securities and Exchange Commission on March 10, 2016 Registration No. |
|
| March 10, 2016 |
OncoMed Pharmaceuticals 10-K (Annual Report) omed-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| March 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (C |
|
| March 10, 2016 |
EX-99.1 2 d157004dex991.htm EX-99.1 Exhibit 99.1 OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2015 Financial Results and 2016 Guidance Projects Two Years’ Cash Runway – without Partner-related Milestones/Opt-ins OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT REDWOOD CITY, Calif., March 10, 2016 – OncoMed Pharmaceuticals, Inc. (Nasda |
|
| March 10, 2016 |
Exhibit 10.9(C) October 12, 2015 Mr. Paul Hastings 61 Hartford Street San Francisco, CA 94114 Re: Change in Control and Severance Agreement Dear Paul: You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to an offer letter dated November 12, 2005, as amended by the Amendment to Employment Agreement dated July 2, 2013 (the “Offer Letter Agreement”), which sets forth, among other things |
|
| March 10, 2016 |
Amended and Restated Form of Change in Control and Severance Agreement for officers Exhibit 10.16 [DATE] [NAME] [ADDRESS] Re: Amended and Restated Change in Control and Severance Agreement Dear [NAME]: You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to a Change in Control and Severance Agreement dated [] (the “Change in Control Agreement”), which sets forth, among other things, the terms and conditions of certain severance benefits payable to you in the event of |
|
| March 10, 2016 |
EX-10.2(D) 2 omed-ex102d48.htm EX-10.2(D) Exhibit 10.2(D) AMENDMENT 3 TO THE COLLABORATION AND OPTION AGREEMENT This Amendment 3 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on November 4, 2015 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United S |
|
| February 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 16, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2015 (Date of Event Which |
|
| February 12, 2016 |
OncoMed Pharmaceuticals SC 13G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ONCOMED PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68234X102 (CUSIP Number) DECEMBER 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 12, 2016 |
OMED / OncoMed Pharmaceuticals, Inc. / MORGENTHALER PARTNERS VII LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock ($0.001 par value) (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2015 (Date of Event Whi |
|
| February 3, 2016 |
OMED / OncoMed Pharmaceuticals, Inc. / US VENTURE PARTNERS VIII L P - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing |
|
| January 25, 2016 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) |
|
| January 25, 2016 |
EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial Management to Conduct Conference Call at 8:30 am ET REDWOOD CITY, Calif. ? January 25, 2016 ? OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 ALPINE c |
|
| January 6, 2016 |
Unassociated Document POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) the Chief Executive Officer of OncoMed Pharmaceuticals, Inc. |
|
| January 6, 2016 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporati |
|
| January 6, 2016 |
OncoMed Pharmaceuticals Appoints Perry Karsen to Board of Directors EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Pharmaceuticals Appoints Perry Karsen to Board of Directors REDWOOD CITY, Calif., January 6, 2016 ? OncoMed Pharmaceuticals, Inc., (NASDAQ: OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the appointment of Perry Karsen to the company?s Board of Directors. Mr. Karsen brings g |
|
| January 5, 2016 |
OncoMed Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2016 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) ( |
|
| January 5, 2016 |
EX-99.1 2 d113293dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Achieves $72.5 Million in Milestone Payments from Celgene; Announces Year-End Cash Balance $70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved Enters 2016 with $227 Million in Pro-Forma Cash REDWOOD CITY, Calif. – January 5, 2016 – OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), today ann |
|
| November 5, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporat |
|
| November 5, 2015 |
OncoMed Pharmaceuticals Reports Third Quarter 2015 Financial Results EX-99.1 Exhibit 99.1 OncoMed Pharmaceuticals Reports Third Quarter 2015 Financial Results REDWOOD CITY, Calif., November 5, 2015 ? OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics, today announced financial results for the quarter ended September 30, 2015. The company ended the third quarter with $175.2 m |
|
| November 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35993 OncoM |
|
| November 5, 2015 |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. |
|
| August 10, 2015 |
EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Pharmaceuticals Announces Second Quarter 2015 Financial Results and Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data REDWOOD CITY, Calif., August 10, 2015 ? OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) today reported financial results for the quarter ended June 30, 2015 and provided an update on progress toward 2015 corporate ob |
|
| August 10, 2015 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporati |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 10, 2015 |
EX-10.1 EXHIBIT 10.1 ONCOMED PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Approved by the Board of Directors on August 28, 2013, as amended October 14, 2013, February 28, 2014 and June 24, 2015 Non-employee members of the board of directors (the “Board”) of OncoMed Pharmaceuticals, Inc. (the “Company”) who are appointed to the Board on or after June 24, 2015 (the “Effective Date |
|
| July 20, 2015 |
Acceleration Request OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, California 94063 July 20, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Johnny Gharib Re: OncoMed Pharmaceuticals, Inc. Registration Statement on Form S-3 (Registration No. 333-204914) Ladies and Gentlemen: In accordance with R |
|
| June 29, 2015 |
OncoMed Pharmaceuticals Appoints Rick Winningham to Board of Directors EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Pharmaceuticals Appoints Rick Winningham to Board of Directors REDWOOD CITY, Calif., June 29, 2015 ? OncoMed Pharmaceuticals, Inc., (NASDAQ: OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the appointment of Rick Winningham to the company?s Board of Directors. Mr. Winningham |
|
| June 29, 2015 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation |
|
| June 26, 2015 |
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) the Chief Executive Officer of OncoMed Pharmaceuticals, Inc. |
|
| June 25, 2015 |
OncoMed Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation |
|
| June 12, 2015 |
EX-1.2 2 d940782dex12.htm EX-1.2 Exhibit 1.2 Execution Version ONCOMED PHARMACEUTICALS INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement June 12, 2015 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) wit |
|
| June 12, 2015 |
EX-4.4 3 d940782dex44.htm EX-4.4 Exhibit 4.4 OncoMed Pharmaceuticals, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. |
|
| June 12, 2015 |
S-3 1 d940782ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on June 12, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 OncoMed Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 38-3572512 (State or other jurisdi |
|
| June 12, 2015 |
STATEMENT REGARDING THE COMPUTATION OF RATIOS EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIOS The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated (in thousands): Three Months Ended March 31, Year Ended December 31, 2015 2014 2013 2012 2011 2010 EARNINGS: Loss before income taxes $ (14,518 ) $ (50,519 ) $ (24,127 ) $ (22,235 ) $ (15,034 ) $ (27,015 ) Plus fixed charges and |
|
| May 7, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d921580d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 7, 2015 |
OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results EX-99.1 2 d921580dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results REDWOOD CITY, Calif., May 7, 2015 — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) today reported financial results for the quarter ended March 31, 2015 and provided an update on progress toward 2015 corporate objectives and clinical development milestones. “Th |
|
| April 29, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d917179d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction |
|
| April 29, 2015 |
OncoMed Pharmaceuticals to Webcast 2015 Research and Development Day on April 29, 2015 EX-99.1 Exhibit 99.1 For Immediate Release OncoMed Pharmaceuticals to Webcast 2015 Research and Development Day on April 29, 2015 Redwood City, Calif., April 23, 2015 - OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, will host a Research and Development (R&D) Day for its institutio |
|
| April 24, 2015 |
OncoMed Pharmaceuticals DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2015 |
OncoMed Pharmaceuticals DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 12, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporation) (Commi |
|
| March 12, 2015 |
2/3 Appendix A HuCAL Antibodies sequences EX-10.3C Exhibit 10.3(C) [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. ONCOMED PHARMACEUTICALS, INC. 800 Chesapeake Drive Redwood City, California 94063 United States of America Attn: Paul J. Hastings, Chief Executive Officer Telecopy: +1-6 |
|
| March 12, 2015 |
Exhibit 10.20(B) [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. CONFIDENTIAL AMENDMENT NO. 1 to the Multi-Product License Agreement dated 22 August 2012 between LONZA SALES AG and ONCOMED PHARMACEUTICALS, INC 1 CONFIDENTIAL THIS AMENDMENT is |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35 |
|
| March 12, 2015 |
EX-99.1 Exhibit 99.1 OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent Highlights REDWOOD CITY, Calif., March 12, 2015 ? OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results for the year and quarter ended Dece |
|
| February 17, 2015 |
OMED / OncoMed Pharmaceuticals, Inc. / MORGENTHALER PARTNERS VII LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock ($0.001 par value) (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2014 (Date of Event Whi |
|
| February 13, 2015 |
OMED / OncoMed Pharmaceuticals, Inc. / Phase4 Partners Ltd - AMENDMENT NO.1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No: 1)* Under the Securities Exchange Act of 1934 (Amendment No. ) OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 13, 2015 |
OMED / OncoMed Pharmaceuticals, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Original Filing)* ONCOMED PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68234X102 (CUSIP Number) DECEMBER 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 11, 2015 |
Hummer - DeltaPoint Schedule 13G Original - 1996 SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 11, 2015 |
OMED / OncoMed Pharmaceuticals, Inc. / DELPHI VENTURES VIII LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing |
|
| February 11, 2015 |
Amendment No. 1 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 11, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* OncoMed Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing |
|
| January 26, 2015 |
OMED / OncoMed Pharmaceuticals, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on January 26, 2015 Registration No. |
|
| January 12, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporat |
|
| January 12, 2015 |
EX-99.1 Exhibit 99.1 OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance Begins 2015 with $232 Million in Cash Potential Milestones from Existing Partnerships in 2015/2016 Projected at Over $150 Million REDWOOD CITY, Calif. – January 12, 2015 – OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells ( |
|
| January 9, 2015 |
OMED / OncoMed Pharmaceuticals, Inc. / VERTICAL FUND I LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ONCOMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68234X102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 4, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2014 ONCOMED PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35993 38-3572512 (State or other jurisdiction of incorporat |
|
| November 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 4, 2014 |
EX-99.1 Exhibit 99.1 OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial and Operating Results Raises Year-End Cash Balance Guidance to Over $225 Million from $215 Million Management to Host Call at 4:30 pm ET to Discuss Quarter and Pipeline Advances REDWOOD CITY, Calif. – November 4, 2014 – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage company developing novel therapeu |
|
| August 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
